The Impact of Cold Spray Use on Thirst Distress, Dry Mouth, and Fluid Intake in Heart Failure Patients DOI Open Access
Amir Ghasemi, Seyed Reza Mazloum,

Tayebe Pourghaznein

et al.

The Journal of Cardiovascular Nursing, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Background People with heart failure frequently experience dry mouth and thirst. More information is currently needed on the effectiveness of practical interventions in reducing these symptoms. Objective This study was conducted to determine effect cold-water spray thirst distress, mouth, fluid intake patients failure. Methods A randomized controlled trial involving 72 a confirmed diagnosis The were randomly assigned either an intervention group that received spray–based program or control routine department care. spraying cold water implemented for 3 days. level measured at beginning end 3-day intervention, data analyzed using SPSS software version 21. Results Before 2 groups showed no significant differences demographic characteristics, such as age gender ( P > .05). average scores distress also identical. However, after had significantly lower (20.2 ± 6.9 vs 27.1 8.5, < .001) (3.5 1 5.2 1.2, compared group. It worth noting there difference between groups. Conclusion concluded effectively reduces

Language: Английский

Financial Toxicity of Medical Management of Heart Failure DOI Creative Commons
Smrithi Sukumar, Jason H. Wasfy, James L. Januzzi

et al.

Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 81(20), P. 2043 - 2055

Published: May 1, 2023

Language: Английский

Citations

25
Rationale and Design of the HERZCHECK trial: Detection of Early Heart Failure Using Telemedicine and CMR in Structurally Weak Regions (NCT05122793) DOI Creative Commons
Sebastian Kelle,

Anna Clara Nolden,

Maximilian Müller

et al.

Journal of Cardiovascular Magnetic Resonance, Journal Year: 2025, Volume and Issue: unknown, P. 101841 - 101841

Published: Jan. 1, 2025

Heart failure (HF) is an imminent global health problem. Yet established screening algorithms for asymptomatic pre-HF, allowing early and effective preventive interventions, are largely lacking. The HERZCHECK trial, conducted in structurally underserved rural regions of North-Eastern Germany, aims to close this gap by evaluating the feasibility, diagnostic efficacy, cost-effectiveness a fully mobile, telemedically-supervised approach, combining cardiac magnetic resonance imaging (CMR) laboratory testing as central elements. trial prospective, randomized controlled employing PROBE (prospective open, blinded endpoint) design. study targets adults aged 40-69 years without history HF, but with at least one following cardiovascular risk factors: hypertension, hypercholesterolemia, obesity, smoking/tobacco consumption, chronic diabetes mellitus, or kidney disease. Participants undergo comprehensive examination including questionnaire-based medical history, testing, CMR baseline. Based on CMR-derived longitudinal strain (GLS), participants classified stratum A (GLS < -15%), B ≥ -15% -11%), C strata being defined pre-HF. 10% all subsequently into two groups, receiving either conventional innovative reports, latter information GLS, guideline-based recommendations, access life-style intervention app prevention. Additionally, treating physicians group granted expert center telemedical enquires. Follow-up assessments performed over 12 months evaluate changes well adverse events quality life. provide blueprint comprehensive, contemporary approach tailored needs targeted population. By implementing representative at-risk cohort, will important new about (a) prevalence pre-HF patients (b) added value economic aspects exams part future mechanisms HF clinical routine care. (NCT05122793).

Language: Английский

Citations

1
Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure DOI Creative Commons
Petra Verdino,

Stacey L. Lee,

Fariba N. Cooper

et al.

British Journal of Pharmacology, Journal Year: 2023, Volume and Issue: 180(15), P. 1965 - 1980

Published: Feb. 13, 2023

Chronic heart failure, a progressive disease with limited treatment options currently available, especially in failure preserved ejection fraction (HFpEF), represents an unmet medical need as well economic burden. The development of novel therapeutic to slow or reverse progression would be highly impactful patients and society. Relaxin-2 (relaxin) is human hormone regulating cardiovascular, renal, pulmonary adaptations during pregnancy. A short-acting recombinant relaxin, Serelaxin, demonstrated short-term symptom relief biomarker improvement acute trials. Here, we present the long-acting relaxin analogue tested chronic failure.LY3540378 protein composed serum albumin-binding VHH domain.LY3540378 potent agonist family peptide receptor 1 (RXFP1) maintains selectivity against RXFP2/3/4 comparable native relaxin. half-life LY3540378 preclinical species extended through high affinity binding domain albumin. When single dose administration, elicited relaxin-mediated pharmacodynamic responses, such reduced osmolality increased renal blood flow rats. In isoproterenol-induced cardiac hypertrophy mouse model, significantly improved isovolumetric relaxation time. monkey cardiovascular safety study, there were no adverse observations from administration LY3540378.LY3540378 suitable clinical candidate, progressing

Language: Английский

Citations

19
Heart disease prediction using machine learning, deep Learning and optimization techniques-A semantic review DOI
Girish S. Bhavekar, Agam Das Goswami, Chafle Pratiksha Vasantrao

et al.

Multimedia Tools and Applications, Journal Year: 2024, Volume and Issue: 83(39), P. 86895 - 86922

Published: July 5, 2024

Language: Английский

Citations

8
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial DOI Creative Commons
Pascal R.D. Clephas, Victor W Zwartkruis, Jishnu Malgie

et al.

European Heart Journal, Journal Year: 2024, Volume and Issue: unknown

Published: May 11, 2024

In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated efficacy of pulmonary artery (PA)-guided HF therapy over standard care in improving quality life and reducing hospitalizations mean PA pressure. This study aimed to evaluate consistency these benefits relation clinically relevant subgroups.

Language: Английский

Citations

7
Chapter 1: The Burden of Heart Failure DOI Creative Commons
Richard E. Pratley,

Xuan Guan,

Richard J. Moro

et al.

The American Journal of Medicine, Journal Year: 2024, Volume and Issue: 137(2), P. S3 - S8

Published: Jan. 4, 2024

Heart failure (HF) affects an estimated 6 million American adults, and the prevalence continues to increase, driven in part by aging of population increases diabetes. In recent decades, improvements survival patients with HF have resulted a growing number individuals living longer HF. its comorbidities are associated substantial impairments physical functioning, emotional well-being, quality life, also markedly increased rates morbidity mortality. As result, management has economic impact on health care system, most costs arising from hospitalization. Clinicians important role helping reduce burden through timely diagnosis as well increasing access effective treatments minimize symptoms, delay progression, hospital admissions. Prevention early will play fundamental efforts large Recent advances pharmacotherapies for potential radically change HF, offering possibility improved life patients.

Language: Английский

Citations

6
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials DOI
Konstantinos Pamporis,

Paschalis Karakasis,

Μarios Sagris

et al.

Current Problems in Cardiology, Journal Year: 2024, Volume and Issue: 49(7), P. 102615 - 102615

Published: April 29, 2024

Language: Английский

Citations

6
Multimodal Prehabilitation in Heart Transplant Recipients Improves Short-Term Post-Transplant Outcomes without Increasing Costs DOI Open Access
Manuel López-Baamonde, M.J. Arguís, Ricard Navarro‐Ripoll

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(11), P. 3724 - 3724

Published: May 28, 2023

(1) Background and aim: This study aimed to investigate the impact of prehabilitation on postoperative outcomes heart transplantation its cost-effectiveness. (2) Methods: single-center, ambispective cohort included forty-six candidates for elective from 2017 2021 attending a multimodal program consisting supervised exercise training, physical activity promotion, nutritional optimization, psychological support. The course was compared control patients transplanted 2014 those contemporaneously not involved in prehabilitation. (3) Results: A significant improvement observed preoperative functional capacity (endurance time 281 vs. 728 s, p < 0.001) quality-of-life (Minnesota score 58 47, = 0.046) after program. No exercise-related events were registered. showed lower rate severity complications (comprehensive complication index 37 31, 0.033), mechanical ventilation (37 20 h, 0.032), ICU stay (7 5 days, 0.01), total hospitalization (23 18 0.008) less need transfer nursing/rehabilitation facilities hospital discharge (31% 3%, 0.009). cost-consequence analysis that did increase surgical process costs. (4) Conclusions: Multimodal before has benefits short-term potentially attributable enhancement status, without cost-increasing.

Language: Английский

Citations

14
The economics of heart failure care DOI Creative Commons
Wei Chen, Paul A. Heidenreich, Alexander T. Sandhu

et al.

Progress in Cardiovascular Diseases, Journal Year: 2024, Volume and Issue: 82, P. 90 - 101

Published: Jan. 1, 2024

Language: Английский

Citations

5
Advances in electrochemical detection of B-type natriuretic peptide as a heart failure biomarker DOI Creative Commons
Yanjun Li, Haitao Xu, Shuang Chen

et al.

International Journal of Electrochemical Science, Journal Year: 2024, Volume and Issue: 19(9), P. 100748 - 100748

Published: Aug. 2, 2024

Heart failure (HF) is a global health crisis with an increasing prevalence, emphasizing the urgent need for effective diagnostic and monitoring strategies. B-type natriuretic peptide (BNP), sensitive specific biomarker, has revolutionized HF management by enabling early detection, risk stratification, treatment guidance. However, conventional methods BNP detection face limitations in sensitivity, specificity, real-time capabilities. Electrochemical biosensors have emerged as promising alternative, combining specificity of biological recognition elements sensitivity electrochemical transduction. This review explores principles, advancements, challenges development detection. Innovative biorecognition elements, signal amplification techniques, nanomaterial-based electrode modifications significantly improved analytical performance these biosensors, achieving impressive limits direct measurements complex samples. Furthermore, integration microfluidic platforms wearable/implantable devices opened new avenues continuous, levels, facilitating personalized precise interventions management.

Language: Английский

Citations

5